These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27312006)

  • 21. Mouse and Human CD1d-Self-Lipid Complexes Are Recognized Differently by Murine Invariant Natural Killer T Cell Receptors.
    Guo T; Chamoto K; Nakatsugawa M; Ochi T; Yamashita Y; Anczurowski M; Butler MO; Hirano N
    PLoS One; 2016; 11(5):e0156114. PubMed ID: 27213277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide.
    Croudace JE; Curbishley SM; Mura M; Willcox CR; Illarionov PA; Besra GS; Adams DH; Lammas DA
    BMC Immunol; 2008 Dec; 9():71. PubMed ID: 19055753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner.
    Aoki T; Takami M; Takatani T; Motoyoshi K; Ishii A; Hara A; Toyoda T; Okada R; Hino M; Koyama-Nasu R; Kiuchi M; Hirahara K; Kimura MY; Nakayama T; Shimojo N; Motohashi S
    Cancer Sci; 2020 Jul; 111(7):2223-2233. PubMed ID: 32324315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control.
    Kinjo Y; Takatsuka S; Kitano N; Kawakubo S; Abe M; Ueno K; Miyazaki Y
    Front Immunol; 2018; 9():1266. PubMed ID: 29928278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Innate immune control of EBV-infected B cells by invariant natural killer T cells.
    Chung BK; Tsai K; Allan LL; Zheng DJ; Nie JC; Biggs CM; Hasan MR; Kozak FK; van den Elzen P; Priatel JJ; Tan R
    Blood; 2013 Oct; 122(15):2600-8. PubMed ID: 23974196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD1d-restricted antigen presentation by Vγ9Vδ2-T cells requires trogocytosis.
    Schneiders FL; Prodöhl J; Ruben JM; O'Toole T; Scheper RJ; Bonneville M; Scotet E; Verheul HM; de Gruijl TD; van der Vliet HJ
    Cancer Immunol Res; 2014 Aug; 2(8):732-40. PubMed ID: 24934445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells.
    Schneiders FL; Huijts CM; Mantici A; Menks MA; Scotet E; Veerhuis R; Verheul HM; de Gruijl TD; van der Vliet HJ
    Clin Immunol; 2015 May; 158(1):92-9. PubMed ID: 25796193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges.
    Dhodapkar MV; Richter J
    Clin Immunol; 2011 Aug; 140(2):160-6. PubMed ID: 21233022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential contribution of dendritic cell CD1d to NKT cell-enhanced humoral immunity and CD8+ T cell activation.
    Joshi SK; Lang GA; Devera TS; Johnson AM; Kovats S; Lang ML
    J Leukoc Biol; 2012 May; 91(5):783-90. PubMed ID: 22331103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancing immunostimulatory function of human embryonic stem cell-derived dendritic cells by CD1d overexpression.
    Zeng J; Shahbazi M; Wu C; Toh HC; Wang S
    J Immunol; 2012 May; 188(9):4297-304. PubMed ID: 22407918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Harnessing CD1d-restricted T cells toward antitumor immunity in humans.
    Neparidze N; Dhodapkar MV
    Ann N Y Acad Sci; 2009 Sep; 1174():61-7. PubMed ID: 19769737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retinoic acid induction of CD1d expression primes chronic lymphocytic leukemia B cells for killing by CD8
    Ghnewa YG; O'Reilly VP; Vandenberghe E; Browne PV; McElligott AM; Doherty DG
    Clin Immunol; 2017 Oct; 183():91-98. PubMed ID: 28780376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Innate Invariant NKT Cell Recognition of HIV-1-Infected Dendritic Cells Is an Early Detection Mechanism Targeted by Viral Immune Evasion.
    Paquin-Proulx D; Gibbs A; Bächle SM; Checa A; Introini A; Leeansyah E; Wheelock CE; Nixon DF; Broliden K; Tjernlund A; Moll M; Sandberg JK
    J Immunol; 2016 Sep; 197(5):1843-51. PubMed ID: 27481843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endocytic pH regulates cell surface localization of glycolipid antigen loaded CD1d complexes.
    Arora P; Kharkwal SS; Ng TW; Kunnath-Velayudhan S; Saini NK; Johndrow CT; Chang YT; Besra GS; Porcelli SA
    Chem Phys Lipids; 2015 Oct; 191():75-83. PubMed ID: 26306469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy.
    Hara A; Koyama-Nasu R; Takami M; Toyoda T; Aoki T; Ihara F; Kobayashi M; Hirono S; Matsutani T; Nakayama T; Iwadate Y; Motohashi S
    Cancer Immunol Immunother; 2021 May; 70(5):1239-1254. PubMed ID: 33128583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A single amino acid defines cross-species reactivity of tree shrew (Tupaia belangeri) CD1d to human invariant natural killer T (iNKT) cells.
    Zhang P; Li D; Stewart-Jones G; Shao X; Zhang Y; Chen Q; Li Y; He YW; Xu XN; Zhang HT
    Immunology; 2009 Dec; 128(4):500-10. PubMed ID: 19863613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses.
    Corgnac S; Perret R; Derré L; Zhang L; Stirnemann K; Zauderer M; Speiser DE; Mach JP; Romero P; Donda A
    Cancer Immunol Immunother; 2013 Apr; 62(4):747-60. PubMed ID: 23242316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role for lysosomal phospholipase A2 in iNKT cell-mediated CD1d recognition.
    Paduraru C; Bezbradica JS; Kunte A; Kelly R; Shayman JA; Veerapen N; Cox LR; Besra GS; Cresswell P
    Proc Natl Acad Sci U S A; 2013 Mar; 110(13):5097-102. PubMed ID: 23493550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.
    Song W; van der Vliet HJ; Tai YT; Prabhala R; Wang R; Podar K; Catley L; Shammas MA; Anderson KC; Balk SP; Exley MA; Munshi NC
    Clin Cancer Res; 2008 Nov; 14(21):6955-62. PubMed ID: 18980990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of lipid antigen presentation in dendritic cells by HIV-1 Vpu interference with CD1d recycling from endosomal compartments.
    Moll M; Andersson SK; Smed-Sörensen A; Sandberg JK
    Blood; 2010 Sep; 116(11):1876-84. PubMed ID: 20530791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.